PUR-FORM MUSE CELL SERIES | PART 7
Why cell identity may matter as much as cell count
When patients ask about a regenerative cell treatment, one of the first questions is usually:
“How many cells am I getting?”
It is a reasonable question. Cell number matters.
But a vial labeled “20 million cells” tells us only how many cells are present. It does not tell us what those cells are, what percentage belongs to the population we actually want, whether those cells remain functional, or what else is present alongside them.
A cell count tells us quantity. It does not tell us biological quality.
That distinction becomes especially important when we talk about MUSE cells.
Not Every “Stem Cell” Is the Same
Many regenerative products are broadly described as containing mesenchymal stem or stromal cells, or MSCs. But an MSC preparation is not one perfectly uniform population of identical cells. Mesenchymal tissues contain different cellular subpopulations with different markers and potentially different biological behaviors.
MUSE cells represent one specialized population within that broader mesenchymal compartment. They are identified in part by SSEA-3 expression and are associated with the combination of characteristics discussed throughout this series: stress endurance, injury-directed homing, pluripotent-like differentiation, immune regulation, and a potent secretome.
That means two vials can contain the same total number of “stem cells” and still be very different biological products.
Twenty Million Cells May Not Mean Twenty Million MUSE Cells
Imagine two vials, each labeled 20 million cells.
One contains a broad MSC population with relatively few MUSE cells. The other has been specifically enriched so that MUSE cells make up a much larger proportion of the preparation.
Those are not biologically equivalent products simply because the total cell count is identical.
This is why regenerative medicine needs to move beyond simple cell-count thinking.
The better questions are:
- What cells are actually present?
- What percentage represents the population we are trying to deliver?
- How was that identity verified?
- And are those cells still capable of performing the functions we expect from them?
The Composition of the Vial May Matter
MUSE cells share some characteristics with conventional MSCs, but the biology is not identical.
MUSE cells have been associated with injury-directed homing through the S1P-S1PR2 pathway, greater stress tolerance, broader differentiation potential, and a distinctive immune-regulatory profile.
This raises an interesting question: What happens if two products contain the same absolute number of MUSE cells, but one contains those cells within a large excess of conventional MSCs while the other is predominantly MUSE cells?
We do not yet have enough human evidence to answer that definitively.
Clinical observations suggest that the cellular composition surrounding the MUSE population may influence the inflammatory and chemotactic environment involved in homing. That remains a hypothesis rather than an established clinical rule.
The vial is an ecosystem too.
The other cells present can release cytokines, respond to inflammatory signals, consume nutrients, and change the biological environment surrounding the MUSE cells.
Product composition may therefore matter in addition to product quantity.
Cell Count and Functional Dose Are Not the Same Thing
If we deliver 20 million cells, we know the numerical dose.
But how many of those cells actually possess the biological characteristics we aim to deliver?
- Can they recognize an injury signal?
- Can they migrate?
- Can they tolerate stress?
- Can they release an appropriate secretome?
- Do they retain the expected phenotype after manufacturing, freezing, storage, and thawing?
A larger number of poorly characterized cells may be biologically very different from a smaller number of well-characterized, functional cells.
That does not mean fewer cells are necessarily better.
It means you must interpret cell number in the context of identity and function.
Viability Is Not the Same as Potency
Another number frequently emphasized in cell therapy is viability.
A preparation might be described as 90% or 95% viable. That is useful information, but it tells us only part of the story.
Viability asks: Is the cell alive?
Potency asks: Can the cell still do what we expect it to do?
Those are not necessarily the same thing.
A cell may still exclude a viability dye and yet have impaired mitochondria, altered surface receptors, reduced migration, or diminished signaling capability.
For MUSE cells, that matters because the features we care about, including homing, stress resistance, signaling, and interaction with injured tissue, are functional behaviors.
Alive is necessary. Functional is better.
A Product Name Is Not an Identity Test
This is why I become cautious when a product is described as “MUSE,” “MUSE-like,” or “MUSE-enriched” without adequate biological characterization.
A product name is not a biological assay.
If we want to know what is truly inside the vial, I think we should evaluate four basic areas.
1. Identity
Are the intended cells actually present?
For MUSE cells, that means appropriate phenotypic characterization, including markers such as SSEA-3, rather than relying on the product label alone.
2. Function
Can the cells perform the biological functions associated with the population?
That might include relevant measures of migration, stress tolerance, signaling, or other validated potency characteristics.
3. Safety
Has the product been appropriately evaluated for sterility, stability, cellular abnormalities, and other quality measures?
4. Manufacturing
Was the product produced consistently from batch to batch?
Manufacturing Is Part of the Biology
- With living cells, manufacturing is not simply what happens before the biology begins.
- Manufacturing changes biology.
- Where the tissue came from matters.
- How the cells were isolated matters.
- Culture conditions matter.
- Expansion matters.
- The number of passages may matter.
- Cryopreservation and thawing matter.
- Storage and handling matter.
A living cell can alter its metabolism, surface receptors, signaling behavior, and functional capabilities depending on how it has been processed.
That makes cellular manufacturing fundamentally different from manufacturing a conventional drug.
A tablet contains a defined chemical dose. A living cell is a responsive biological system.
So manufacturing consistency is not merely a quality-control concern. It is part of the therapeutic product itself.
The Source Tissue Matters Too
MUSE cells can be found in several mesenchymal tissue sources, including bone marrow, adipose tissue, Wharton’s jelly, and placenta.
But the source containing the greatest number of cells is not automatically the best source for every purpose.
Donor biology, cell quality, scalability, manufacturing consistency, and the intended clinical application all matter.
We will explore those differences more closely later in this series.
Where a cell comes from is part of what that cell product is.
More Is Not Automatically Better
It is tempting to think of cell therapy as a simple numbers game.
If 20 million cells might be useful, perhaps 40 million must be better. And if 40 million are better, perhaps 100 million would be better still.
Biology rarely works that way.
Dose matters, but so do cell identity, product composition, potency, route of administration, vascular behavior, target tissue, and clinical objective.
There is currently no universal MUSE-cell dosing standard. Published dosing has been protocol- and indication-specific.
So the goal should not simply be the largest possible number of cells.
It should be the right cells, appropriately characterized, at a biologically sensible dose.
The Patient Is Part of the Equation Too
Even an excellent cell product does not work in isolation.
It enters a patient.
One patient may have substantial inflammation. Another may have poor microvascular perfusion. Another may have oxidative stress, fibrosis, or significant immune activation.
Regenerative therapy is therefore a two-sided equation.
On one side are cell factors such as identity, potency, viability, dose, route, and homing capacity.
On the other are host factors such as inflammation, oxidative stress, perfusion, oxygenation, and immune activation.
The biology of the product matters. The biology of the patient matters. The interaction between the two may ultimately determine the response.
The Better Question
When regenerative medicine was younger, we tended to ask:
- How many stem cells are we giving?
- What exactly is in the vial?
- Are they the cells we think they are?
- Are they functional?
- How were they manufactured?
- What other cells are present?
- What evidence shows the finished product still has the biology we are trying to deliver?
Cell count remains important, but it is only one piece of the puzzle:
- Identity matters.
- Composition matters.
- Viability matters.
- Potency matters.
- Manufacturing matters.
- Two vials can contain exactly the same number of cells and still represent very different biological products.
The better question may be:
“What cells am I actually getting, and what are they capable of doing?”
Dr. P
